Skip to content
mapperlab
← Dashboard
Stock

RARE

ULTRAGENYX PHARMACEUTICAL INC.
Latest close $247 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
11
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Nov 14, 2016May 12, 2023Nov 14, 2024May 15, 2026
Now
7

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$52$24-53%
Two Sigma Investments$52$24-53%
D.E. Shaw$52$24-53%
AQR Capital Management$52$24-53%
Millennium Management$52$24-53%
Point72 Asset Management re-entered$52$24-53%
Renaissance Technologies$49$24-50%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Duquesne Family Office→ $30-38%
Bridgewater Associates→ $41-13%
Maverick Capital→ $71-35%
JANA Partners→ $59-28%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Ultragenyx Pharmaceutical Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
10
Filings · last 90d
28
Total on file
538
Recent SEC buffer
Most recent
Jun 1, 2026

30d / 90d windows measured from Jun 1, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 538 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · ULTRAGENYX PHARMACEUTICAL INC.

Annual figures sourced directly from ULTRAGENYX PHARMACEUTICAL INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$673M
FY2025+20% YoY
Net income
-$575M
FY2025-1% YoY
EPS (diluted)
$-5.83
FY2025+7% YoY
Free cash flow(?)
-$472M
FY2025-12% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Ultragenyx Pharmaceutical Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$25$24-3%
Duquesne Family OfficeQ4 2024Q3 2025$48$30-38%
Renaissance TechnologiesQ4 2024open$49$24-50%
Citadel AdvisorsQ3 2024open$52$24-53%
Two Sigma InvestmentsQ3 2024open$52$24-53%
D.E. ShawQ3 2024open$52$24-53%
AQR Capital ManagementQ3 2024open$52$24-53%
Millennium ManagementQ3 2024open$52$24-53%
Point72 Asset ManagementQ3 2024Q4 2025$52$33-36%
Bridgewater AssociatesQ2 2023Q2 2024$47$41-13%
Maverick CapitalQ2 2021Q1 2022$110$71-35%
JANA PartnersQ4 2016Q2 2017$82$59-28%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.